Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Jinadankang injection for acute gouty arthritis
CTR20223136Phase 3Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Jinadankang in acute gout flare, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Dec 2022; status: completed.
02
Drugs
Jinadankang
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20223136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223136.